Clinical Trials

102 enrolled

Prostatic Neoplasms

NCT04964934 2026-04-21

SERENA-6

315 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05296798 2026-04-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

922 enrolled

Breast Neoplasms

NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT02531516 2026-04-13

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

1,503 enrolled

Prostatic Neoplasms

NCT04325828 2026-04-13

YATAGARASU

31 enrolled 15 charts

Head & Neck

Salivary Gland Neoplasms

NCT04037254 2026-04-06

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Phase 1/2 Completed

22 enrolled 13 charts

Prostatic Neoplasms

NCT06065748 2026-04-06

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06382948 2026-04-03

ADELA

Phase 3 Recruiting

240 enrolled

Advanced Breast Cancer

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT06832774 2026-03-25

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

192 enrolled

Prostate Cancer Metastatic Disease

NCT04576455 2026-03-20

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

303 enrolled 23 charts

Breast Neoplasms

NCT07476001 2026-03-17

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

12 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

260 enrolled

Gynecologic

Endometrial Neoplasms

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07466498 2026-03-12

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

60 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT06379217 2026-03-11

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

31 enrolled

EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT07142551 2026-03-11

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

60 enrolled

Prostatic Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Gynecologic

Ovarian Neoplasms

NCT00936390 2026-03-06

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

1,538 enrolled 37 charts

Prostatic Neoplasms

NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

239 enrolled 38 charts

Prostatic Neoplasms

NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Phase 1 Completed

10 enrolled

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

100 enrolled

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

NCT04546009 2026-02-20

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

992 enrolled

Breast Neoplasms

NCT04961996 2026-02-20

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

4,170 enrolled

Breast Neoplasms

NCT04983095 2026-02-17

METRO

Phase NA Recruiting

118 enrolled

Phase 1 Active not recruiting

Prostate Cancer Metastatic

NCT03332797 2026-02-13

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

181 enrolled

Breast Neoplasms

NCT00066690 2026-02-06

SOFT

3,066 enrolled 15 charts

Breast Neoplasms

NCT00066703 2026-02-06

TEXT

2,672 enrolled 14 charts

Breast Neoplasms

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

373 enrolled